{"entity":{"id":"nct07551635","kind":"trial","name":"SMARCA4/2 Inhibitor for POU2F3-Positive SCLC","aka":[],"tldr":"A phase 2 trial in lung cancer, run by Dana-Farber Cancer Institute, not yet recruiting.","summary":"SMARCA4/2 Inhibitor for POU2F3-Positive SCLC is a phase 2, interventional study registered as NCT07551635 by Dana-Farber Cancer Institute, with a registry enrolment figure of 20 participants, started 2026-09-04 and due to reach its primary completion in 2028-01-31. Interventions recorded: FHD-286. Conditions listed: Small Cell Lung Cancer. Primary outcome: Objective Response Rate (ORR). Lung eligibility wording from the registry: \"* Histologically or cytologically confirmed extensive stage SCLC with documented disease progression or recurrence after prior platinum-based therapy with or without checkpoint inhibitor\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07551635","url":"https://clinicaltrials.gov/study/NCT07551635"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["foghorn-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07551635","phase":"2","setting":"A Phase 2 Study of SMARCA4/2 Inhibitor (FHD-286) for POU2F3-Positive Small-Cell Lung Cancer","sponsor":"Dana-Farber Cancer Institute","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07551635/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"company":[{"id":"foghorn-therapeutics","kind":"company","name":"Foghorn Therapeutics","route":"/companies/foghorn-therapeutics/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}